Asset Details
Do you wish to reserve the book?
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Do you wish to request the book?
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
2019
Overview
We examined the influence of common preanalytical factors on the measurement of Alzheimer's disease–specific biomarkers in human plasma.
Amyloid β peptides (Aβ[1-40], Aβ[1-42]) and total Tau plasma concentrations were quantified using fully automated Roche Elecsys assays.
Aβ(1-40), Aβ(1-42), and total Tau plasma concentrations were not affected by up to three freeze/thaw cycles, up to five tube transfers, the collection tube material, or the size; circadian rhythm had a minor effect. All three biomarkers were influenced by the anticoagulant used, particularly total Tau. Aβ concentrations began decreasing 1 hour after blood draw/before centrifugation and decreased by up to 5% and 10% at 2 and 6 hours, respectively. For separated plasma, time to measurement influenced Aβ levels by up to 7% after 6 hours and 10% after 24 hours.
Our findings provide guidance for standardizing blood sample collection, handling, and storage to ensure reliable analysis of Alzheimer's disease plasma biomarkers in routine practice and clinical trials.
•Blood-based Alzheimer's disease biomarkers were measured with fully automated and highly precise Roche Elecsys assays.•Preanalytical sample handling affected measured concentrations of biomarkers.•Time between sample collection and centrifugation, and between centrifugation and measurement, impacted the measured concentrations of Aβ peptides.•Type of anticoagulant substantially affected measured levels of total Tau.•Recommendations for standardized sample collection and processing are provided.
Publisher
Elsevier Inc,John Wiley & Sons, Inc,Elsevier,Wiley
Subject
